India's Syngene International acquires first US biologics facility for $36.5 million

India's Syngene International has agreed to acquire its first biologics facility in the U.S. from Emergent Manufacturing for $36.5 million. This move aims to expand Syngene's capabilities in the Northeast U.S. and reduce dependence on China, with the facility expected to be operational by mid-2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IT3gfWs
via IFTTT